Advertisement

Topics

Allegro’s Luminate succeeds in phase 2 diabetic macular edema trial

05:01 EDT 10 Aug 2017 | Pharmaceutical Business Review

Allegro Ophthalmics' Luminate integrin peptide therapy has passed a phase 2 trial in diabetic macular edema (DME) patients by meeting its primary endpoint when used as a sequential treatment.

Original Article: Allegro’s Luminate succeeds in phase 2 diabetic macular edema trial

NEXT ARTICLE

More From BioPortfolio on "Allegro’s Luminate succeeds in phase 2 diabetic macular edema trial"

Quick Search
Advertisement
 

Relevant Topic

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...